Literature DB >> 35000148

Pseudopheochromocytoma: an Uncommon Cause of Severe Hypertension.

Christie G Turin1, Debbie L Cohen2.   

Abstract

PURPOSE OF REVIEW: Pseudopheochromocytoma or paroxysmal hypertension is an underrecognized condition that requires a thorough investigation of secondary causes of hypertension. In this review, we aim to provide an overview of pathogenesis, clinical manifestations, biochemical evaluation, and potential therapeutic options to manage patients with pseudopheochromocytoma. RECENT
FINDINGS: The pathogenesis of this condition has not been completely elucidated but certain patients show overactivity of the sympathetic nervous system and present with elevated epinephrine and dopamine levels. Workup should include a proper evaluation of blood pressure in distinct clinical scenarios, including ambulatory blood pressure monitoring. Management should be focused on treatment of acute hypertensive episodes and prevention of paroxysms. Treatment of patients with pseudopheochromocytoma should be individualized. Psychopharmacotherapy and psychotherapeutic interventions play an important role in controlling patients' symptoms.
© 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  Catecholamines excess; Labile hypertension; Paroxysmal hypertension; Pseudopheochromocytoma

Mesh:

Year:  2022        PMID: 35000148     DOI: 10.1007/s11886-021-01624-x

Source DB:  PubMed          Journal:  Curr Cardiol Rep        ISSN: 1523-3782            Impact factor:   2.931


  17 in total

Review 1.  Severe paroxysmal hypertension (pseudopheochromocytoma): understanding the cause and treatment.

Authors:  S J Mann
Journal:  Arch Intern Med       Date:  1999-04-12

2.  Occurrence of pheochromocytoma in Rochester, Minnesota, 1950 through 1979.

Authors:  C M Beard; S G Sheps; L T Kurland; J A Carney; J T Lie
Journal:  Mayo Clin Proc       Date:  1983-12       Impact factor: 7.616

3.  Clonidine-suppression test: a useful aid in the diagnosis of pheochromocytoma.

Authors:  E L Bravo; R C Tarazi; F M Fouad; D G Vidt; R W Gifford
Journal:  N Engl J Med       Date:  1981-09-10       Impact factor: 91.245

Review 4.  Recent advances in genetics, diagnosis, localization, and treatment of pheochromocytoma.

Authors:  K Pacak; W M Linehan; G Eisenhofer; M M Walther; D S Goldstein
Journal:  Ann Intern Med       Date:  2001-02-20       Impact factor: 25.391

5.  Sympathoadrenal function in patients with paroxysmal hypertension: pseudopheochromocytoma.

Authors:  Yehonatan Sharabi; David S Goldstein; Oladi Bentho; Ahmed Saleem; Sandra Pechnik; Marilla F Geraci; Courtney Holmes; Karel Pacak; Graeme Eisenhofer
Journal:  J Hypertens       Date:  2007-11       Impact factor: 4.844

Review 6.  Severe paroxysmal hypertension (pseudopheochromocytoma).

Authors:  Samuel J Mann
Journal:  Curr Hypertens Rep       Date:  2008-02       Impact factor: 5.369

Review 7.  Current progress and future challenges in the biochemical diagnosis and treatment of pheochromocytomas and paragangliomas.

Authors:  G Eisenhofer; G Siegert; J Kotzerke; S R Bornstein; K Pacak
Journal:  Horm Metab Res       Date:  2008-05       Impact factor: 2.936

8.  Call to action on use and reimbursement for home blood pressure monitoring: executive summary: a joint scientific statement from the American Heart Association, American Society Of Hypertension, and Preventive Cardiovascular Nurses Association.

Authors:  Thomas G Pickering; Nancy Houston Miller; Gbenga Ogedegbe; Lawrence R Krakoff; Nancy T Artinian; David Goff
Journal:  Hypertension       Date:  2008-05-22       Impact factor: 10.190

9.  Blood pressure response to the Valsalva maneuver in pheochromocytoma and pseudopheochromocytoma.

Authors:  M Hamada; Y Shigematsu; M Mukai; Y Kazatani; T Kokubu; K Hiwada
Journal:  Hypertension       Date:  1995-02       Impact factor: 10.190

10.  Increased plasma dopamine in patients presenting with the pseudopheochromocytoma quandary: retrospective analysis of 10 years' experience.

Authors:  O Kuchel
Journal:  J Hypertens       Date:  1998-10       Impact factor: 4.844

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.